Cargando…

Approach to the Adult Acute Lymphoblastic Leukemia Patient

During recent decades, understanding of the molecular mechanisms of acute lymphoblastic leukemia (ALL) has improved considerably, resulting in better risk stratification of patients and increased survival rates. Age, white blood cell count (WBC), and specific genetic abnormalities are the most impor...

Descripción completa

Detalles Bibliográficos
Autores principales: Sas, Valentina, Moisoiu, Vlad, Teodorescu, Patric, Tranca, Sebastian, Pop, Laura, Iluta, Sabina, Pasca, Sergiu, Blag, Cristina, Man, Sorin, Roman, Andrei, Constantinescu, Catalin, Rus, Ioana, Buse, Mihail, Fetica, Bogdan, Marian, Mirela, Selicean, Cristina, Berindan-Neagoe, Ioana, Petrushev, Bobe, Bumbea, Horia, Tanase, Alina, Zdrenghea, Mihnea, Fuji, Shigeo, Kitano, Shigehisa, Tomuleasa, Ciprian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722778/
https://www.ncbi.nlm.nih.gov/pubmed/31390838
http://dx.doi.org/10.3390/jcm8081175
_version_ 1783448618320003072
author Sas, Valentina
Moisoiu, Vlad
Teodorescu, Patric
Tranca, Sebastian
Pop, Laura
Iluta, Sabina
Pasca, Sergiu
Blag, Cristina
Man, Sorin
Roman, Andrei
Constantinescu, Catalin
Rus, Ioana
Buse, Mihail
Fetica, Bogdan
Marian, Mirela
Selicean, Cristina
Berindan-Neagoe, Ioana
Petrushev, Bobe
Bumbea, Horia
Tanase, Alina
Zdrenghea, Mihnea
Fuji, Shigeo
Kitano, Shigehisa
Tomuleasa, Ciprian
author_facet Sas, Valentina
Moisoiu, Vlad
Teodorescu, Patric
Tranca, Sebastian
Pop, Laura
Iluta, Sabina
Pasca, Sergiu
Blag, Cristina
Man, Sorin
Roman, Andrei
Constantinescu, Catalin
Rus, Ioana
Buse, Mihail
Fetica, Bogdan
Marian, Mirela
Selicean, Cristina
Berindan-Neagoe, Ioana
Petrushev, Bobe
Bumbea, Horia
Tanase, Alina
Zdrenghea, Mihnea
Fuji, Shigeo
Kitano, Shigehisa
Tomuleasa, Ciprian
author_sort Sas, Valentina
collection PubMed
description During recent decades, understanding of the molecular mechanisms of acute lymphoblastic leukemia (ALL) has improved considerably, resulting in better risk stratification of patients and increased survival rates. Age, white blood cell count (WBC), and specific genetic abnormalities are the most important factors that define risk groups for ALL. State-of-the-art diagnosis of ALL requires cytological and cytogenetical analyses, as well as flow cytometry and high-throughput sequencing assays. An important aspect in the diagnostic characterization of patients with ALL is the identification of the Philadelphia (Ph) chromosome, which warrants the addition of tyrosine kinase inhibitors (TKI) to the chemotherapy backbone. Data that support the benefit of hematopoietic stem cell transplantation (HSCT) in high risk patient subsets or in late relapse patients are still questioned and have yet to be determined conclusive. This article presents the newly published data in ALL workup and treatment, putting it into perspective for the attending physician in hematology and oncology.
format Online
Article
Text
id pubmed-6722778
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67227782019-09-10 Approach to the Adult Acute Lymphoblastic Leukemia Patient Sas, Valentina Moisoiu, Vlad Teodorescu, Patric Tranca, Sebastian Pop, Laura Iluta, Sabina Pasca, Sergiu Blag, Cristina Man, Sorin Roman, Andrei Constantinescu, Catalin Rus, Ioana Buse, Mihail Fetica, Bogdan Marian, Mirela Selicean, Cristina Berindan-Neagoe, Ioana Petrushev, Bobe Bumbea, Horia Tanase, Alina Zdrenghea, Mihnea Fuji, Shigeo Kitano, Shigehisa Tomuleasa, Ciprian J Clin Med Article During recent decades, understanding of the molecular mechanisms of acute lymphoblastic leukemia (ALL) has improved considerably, resulting in better risk stratification of patients and increased survival rates. Age, white blood cell count (WBC), and specific genetic abnormalities are the most important factors that define risk groups for ALL. State-of-the-art diagnosis of ALL requires cytological and cytogenetical analyses, as well as flow cytometry and high-throughput sequencing assays. An important aspect in the diagnostic characterization of patients with ALL is the identification of the Philadelphia (Ph) chromosome, which warrants the addition of tyrosine kinase inhibitors (TKI) to the chemotherapy backbone. Data that support the benefit of hematopoietic stem cell transplantation (HSCT) in high risk patient subsets or in late relapse patients are still questioned and have yet to be determined conclusive. This article presents the newly published data in ALL workup and treatment, putting it into perspective for the attending physician in hematology and oncology. MDPI 2019-08-06 /pmc/articles/PMC6722778/ /pubmed/31390838 http://dx.doi.org/10.3390/jcm8081175 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sas, Valentina
Moisoiu, Vlad
Teodorescu, Patric
Tranca, Sebastian
Pop, Laura
Iluta, Sabina
Pasca, Sergiu
Blag, Cristina
Man, Sorin
Roman, Andrei
Constantinescu, Catalin
Rus, Ioana
Buse, Mihail
Fetica, Bogdan
Marian, Mirela
Selicean, Cristina
Berindan-Neagoe, Ioana
Petrushev, Bobe
Bumbea, Horia
Tanase, Alina
Zdrenghea, Mihnea
Fuji, Shigeo
Kitano, Shigehisa
Tomuleasa, Ciprian
Approach to the Adult Acute Lymphoblastic Leukemia Patient
title Approach to the Adult Acute Lymphoblastic Leukemia Patient
title_full Approach to the Adult Acute Lymphoblastic Leukemia Patient
title_fullStr Approach to the Adult Acute Lymphoblastic Leukemia Patient
title_full_unstemmed Approach to the Adult Acute Lymphoblastic Leukemia Patient
title_short Approach to the Adult Acute Lymphoblastic Leukemia Patient
title_sort approach to the adult acute lymphoblastic leukemia patient
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722778/
https://www.ncbi.nlm.nih.gov/pubmed/31390838
http://dx.doi.org/10.3390/jcm8081175
work_keys_str_mv AT sasvalentina approachtotheadultacutelymphoblasticleukemiapatient
AT moisoiuvlad approachtotheadultacutelymphoblasticleukemiapatient
AT teodorescupatric approachtotheadultacutelymphoblasticleukemiapatient
AT trancasebastian approachtotheadultacutelymphoblasticleukemiapatient
AT poplaura approachtotheadultacutelymphoblasticleukemiapatient
AT ilutasabina approachtotheadultacutelymphoblasticleukemiapatient
AT pascasergiu approachtotheadultacutelymphoblasticleukemiapatient
AT blagcristina approachtotheadultacutelymphoblasticleukemiapatient
AT mansorin approachtotheadultacutelymphoblasticleukemiapatient
AT romanandrei approachtotheadultacutelymphoblasticleukemiapatient
AT constantinescucatalin approachtotheadultacutelymphoblasticleukemiapatient
AT rusioana approachtotheadultacutelymphoblasticleukemiapatient
AT busemihail approachtotheadultacutelymphoblasticleukemiapatient
AT feticabogdan approachtotheadultacutelymphoblasticleukemiapatient
AT marianmirela approachtotheadultacutelymphoblasticleukemiapatient
AT seliceancristina approachtotheadultacutelymphoblasticleukemiapatient
AT berindanneagoeioana approachtotheadultacutelymphoblasticleukemiapatient
AT petrushevbobe approachtotheadultacutelymphoblasticleukemiapatient
AT bumbeahoria approachtotheadultacutelymphoblasticleukemiapatient
AT tanasealina approachtotheadultacutelymphoblasticleukemiapatient
AT zdrengheamihnea approachtotheadultacutelymphoblasticleukemiapatient
AT fujishigeo approachtotheadultacutelymphoblasticleukemiapatient
AT kitanoshigehisa approachtotheadultacutelymphoblasticleukemiapatient
AT tomuleasaciprian approachtotheadultacutelymphoblasticleukemiapatient
AT approachtotheadultacutelymphoblasticleukemiapatient